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Abstract
Plasmodium falciparum infection is known to be associated with a spectrum of systemic
complications ranging from mild and self-limiting to life-threatening. This case report illustrates a
patient who had a protracted course in hospital due to several rare complications of falciparum
malaria. A 21-year old man presented with a five-day history of high-grade fever, jaundice and
abdominal pain and a two-day history of altered conscious state. A diagnosis of severe falciparum
malaria was made based on the clinical presentation and a positive blood smear with parasitaemia
of 45%. Despite adequate anti-malarial therapy with artesunate, the patient had persistent and
worsening abdominal pain. Investigations suggested a diagnosis of acute pancreatitis, a rare
association with falciparum malaria. However, in spite of supportive therapy for acute pancreatitis
and a 10-day course of intravenous artesunate and oral doxycycline at recommended doses, he
continued to be febrile with peripheral blood smear showing persistence of ring forms. Antimalarial
therapy was, therefore, changed to quinine on the suspicion of possible artesunate resistance. On
the 17th  day of stay in hospital, the patient developed generalized tonic-clonic seizures.
Computerized tomography of the brain showed bilateral fronto-parietal subdural haematomas that
were surgically drained. His fever persisted beyond 30-days despite broad-spectrum antibiotics,
quinine therapy and negative malarial smears. A possibility of drug fever was considered and all
drugs were ceased. He subsequently became afebrile and was discharged on the 38th hospital
admission day. Recognition of complications and appropriate management at each stage facilitated
successful outcome. This report has been presented to highlight the occurrence of several rare
complications of falciparum malaria in the same patient.
Background
Falciparum malaria is a common disorder in the tropics
associated with myriad complications that can often be
life-threatening and fatal [1]. A 21 year old man presented
with a mixed infection with falciparum and vivax malaria.
His course in hospital was complicated by the develop-
ment of acute pancreatitis, bilateral subdural haematomas
and probable drug fever and artesunate resistance.
Case presentation
A 21-year-old male, a mechanic by profession, presented
to the accident and emergency department with a 5-day
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history of fever, jaundice and generalized abdominal pain
and a 2-day history of altered conscious state. There was
no significant past medical history nor was there a history
of substance abuse.
Clinical examination at the time of presentation revealed
a young man who was drowsy but arousable, conscious
and oriented. He was febrile (101.5°F), had icterus and
exhibited a flapping tremor. He was hemodynamically
stable. Systemic examination was unremarkable except for
generalized tenderness and mild hepatosplenomegaly on
abdominal examination. Investigations on admission are
summarized in Table 1. Of note were anaemia (Hb 7.2
gm/dl), thrombocytopaenia (35,000/cumm), renal fail-
ure (serum creatinine 5.8 mg/dl) and marked hyperbi-
lirubinaemia (total bilirubin 53.6 mg/dl). Peripheral
blood smear was positive for Plasmodium falciparum and
Plasmodium vivax gametocytes and ring stages, with
marked parasitaemia of 45%. A diagnosis of severe falci-
parum malaria was made and treatment was initiated with
intravenous artesunate (140 mg at admission and at 12
hours, dose calculated based on an estimated weight of 65
kg) and oral doxycycline therapy (100-mg twice daily) in
the emergency department. The dose of artesunate was
increased to 180 mg intravenously daily in the intensive
care unit. Broad-spectrum antibiotics (intravenous
cefepime 1-gm twice daily) were added to cover for a co-
existent gram negative sepsis. In view of the high parasitic
index and severe anaemia at presentation, three units of
packed red cells were administered to the patient and 250
ml of blood removed from the patient in a partial
exchange transfusion. A complete ml to ml exchange
transfusion was not performed as the haemoglobin value
reduced after the first exchange to 5.2 g%. The three units
of packed cells and the partial exchange transfusion
reduced the parasitaemia from 45% at admission to 3.5%
in 24 hours (Figure 1).
He was admitted to the intensive care unit (ICU) for treat-
ment and monitoring. In the ICU, his acute renal failure
was initially managed conservatively by achieving ade-
quate filling pressures (central venous pressure), mainte-
nance of blood pressure and measures to correct
hyperkalemia. However, in view of persistent renal failure
and hyperkaliaemia that were refractory to medical ther-
apy, dialysis was initiated and continued till renal recov-
ery. On the second day following ICU admission, his
abdominal pain worsened with the development of
abdominal guarding and rigidity. Investigations suggested
a diagnosis of acute pancreatitis with serum amylase and
lipase levels of 1712 U/L (Reference range 0–200 U/L)
and 5217 U/L (reference range 0–190 U/L) respectively. A
Table 1: Laboratory data
Variable Value Reference range
Haematologic
Haemoglobin (g %) 7.2 10.0 – 15.5
White-cell count (/cu mm) 9100 4000 – 11000
Neutrophils (%) 52 1.8 – 7.5
Platelets (/cu mm) 35000 150000 – 400000
International normalized ratio 1.18 0.8 – 1.2
Activated Partial thromboplastin time (sec) 36.7 23.8 – 37.4
Biochemical
Sodium (mmol/l) 124 137 – 145
Potassium (mmol/l) 6 3.5 – 5.0
Bicarbonate (mmol/l) 8 22 – 29
Blood urea (mmol/l) 9 2.7 – 8.0
Creatinine (mg%) 5.8 0.5–1.4
Total Bilirubin (mg%) 53.6 0.5–1.4
Direct Bilirubin(mg%) 23.0
Albumin (g%) 2.8 3.5–5.0
AST (U/L) 197 8–40
ALT (U/l) 101 5–35
ALP (U/l) 112 40–125
Arterial blood gas (on FiO2of 0.21)
pH 7.22 7.35 – 7.45
PaO2 (mm Hg) 187 60 – 90
PaCO2 (mm Hg) 35.9 35 – 45
Bicarbonate (mmol/l) 14 22 – 29
Base Excess -12.8 -2 to 2Malaria Journal 2008, 7:97 http://www.malariajournal.com/content/7/1/97
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non-contrast computed tomography (CT) scan of the
abdomen showed bulky pancreas with significant peri-
pancreatic fat stranding (Figure 2). C-reactive protein was
> 190 (Reference range-0–6 mg/L). There was no evidence
of a hollow viscus perforation.
The acute pancreatitis was managed with analgesics,
hydration and supportive therapy. A naso-jejunal tube
was inserted to facilitate nutritional supplementation and
antibiotics were changed to imipenem in view of severe
pancreatitis. However, fever persisted even after ten days
of artesunate therapy with the presence of ring forms of
falciparum malaria (parasitemia not quantifiable) on the
peripheral smear. He was initiated on intravenous qui-
nine therapy on the suspicion of artesunate resistance/
failure. Following initiation of quinine therapy, the ring
forms were not demonstrable on the peripheral smear.
His course was further complicated by urinary tract infec-
tion, with > 100000 colonies/ml of Escherichia coli and
Pseudomonas aeruginosa grown from a catheter specimen of
urine.
On Day 17, the patient developed one episode of general-
ized tonic clonic seizures with post-ictal drowsiness. A CT
scan of the brain showed features of acute bi fronto-tem-
poral subdural haematoma with no mass effect (Figure 3).
He was initiated on gabapentin 300 mg twice daily (sub-
sequently increased to 300 mg thrice daily), in addition to
clobazam 10 mg once a day, at the advice of the neurolo-
gist. The subdural haematomas were surgically drained by
the neurosurgeons. His consciousness improved and he
had no further seizures.
However, his fever did not resolve despite appropriate
anti-biotic therapy. Search for a cause for fever including
nosocomial infections and sepsis were negative. A diagno-
sis of drug fever was proposed and all medications were
ceased. After 38-days of admission, on becoming afebrile,
and free of ring stages on peripheral smear, he was dis-
charged on a fourteen-day course of primaquine.
Discussion
The occurrence of several rare complications in the same
patient is not common. Although abdominal pain is a fre-
quent symptom in malaria, in this patient, the persistent
and worsening abdominal pain was related to severe pan-
creatitis. Abdominal pain and vomiting are reported to be
more often associated with falciparum infections than
with vivax [1]. The causes of abdominal pain in malaria
are protean (Table 2) and include acalculous cholecystitis
[2], acute surgical abdomen [3], splenic rupture [4],
splenic infarction [5], splenic torsion [6] and hepatitis/
hepatomegaly [1]. Abdominal pain has also been
described as part of acute renal failure and algid malaria
[7]. The presence of abdominal pain and hepatomegaly
has been shown to be associated with a higher mortality
[7].
Pancreatitis is an unusual cause of abdominal pain in
malaria with less than 10 cases reported worldwide. There
have been isolated reports of a 17-year-old man [8], a 26-
year old man [9], a 40-year old man [10] and a 58-year old
woman [10] with falciparum malaria and pancreatitis.
The parasitaemia in three of these patients [8,10] were low
(0.5 to 1.5%). None of these patients had more than one
WHO criteria for severe falciparum malaria. There has
also been a previous report of a 19-year old girl with acute
Non contrast computed tomography (CT) scan of the abdo- men showing a bulky pancreas (white arrow) with peri-pan- creatic fat stranding (black arrow) suggestive of acute  pancreatitis Figure 2
Non contrast computed tomography (CT) scan of the abdo-
men showing a bulky pancreas (white arrow) with peri-pan-
creatic fat stranding (black arrow) suggestive of acute 
pancreatitis.
Sequential laboratory parameters of the patient over time Figure 1
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pancreatitis and adult respiratory distress syndrome in
association with malaria [11]. This young man did not
manifest acute respiratory distress syndrome either with
severe malaria or with acute pancreatitis.
The proposed pathophysiological mechanisms that result
in pancreatitis are capillary blockage by parasitized RBCs
and acute haemolysis [10]. Occlusion of blood vessels of
the pancreas with parasitized RBCs and rosettes have been
demonstrated in autopsy studies [8]. There has been no
correlation between the infestation index and the occur-
rence of pancreatitis in these patients [12]. The successful
outcomes of patients manifesting pancreatitis in earlier
reports and in the patient reported here are encouraging.
It is possible that the incidence of pancreatitis is much
higher than what is reported and may be due the failure to
screen for pancreatitis as a cause of abdominal pain in
these patients. It should also be remembered that an iso-
lated increase in lipase levels may not by itself suggest
pancreatitis, particularly in the critically ill patient [13]. In
a recent study, critically ill patients who had a positive
finding on imaging had mean peak lipase levels of 2, 231
± 715 U/L [13], suggesting that higher lipase level thresh-
olds may need to be used to identify critically ill patients
who would benefit from further radiological assessment.
The patient in question had a very high lipase level (5217
U/L) and radiological evidence of acute pancreatitis.
The reason for the persistence of parasitaemia on Day 10
was not immediately apparent. The possibilities consid-
ered were inadequate dose of anti-malarial therapy, "inef-
fective" anti-malarial drug, primary drug resistence to
artesunate or delayed parasitic clearance due to surgical or
functional asplenia. Although it was not possible to get an
accurate weight of the patient on admission as he was crit-
ically ill, he was estimated to be around 65 kg. His body
weight on the 10th hospital day, when he was able to
stand, was 50 kg and it was estimated that he had lost
about 20% of his body weight during his critical illness.
The dose of 140 mg of artesunate administered in the
emergency department was thought to be inadequate and
this was increased to 180 mg following ICU admission
(from the 12-hour dose). The dose regimen of artesunate,
of 2.4 mg/kg of artesunate at 0, 12, 24 hours and subse-
quently daily, administered to the patient based on the
SEAQUAMAT trial [14], was considered to be adequate.
In-effective anti-malarial therapy due to poor quality of
the drug or fake anti-malarial drugs could have also con-
tributed to persistent parasitaemia. The brand of artesu-
nate bought from the hospital pharmacy by the relatives
was from a reputed manufacturer that has its presence in
30 countries with more than 300 registrations. Although
the efficacy of the anti-malarial drug could not be assessed
by means of a bio-assay, the absence of lack of efficacy in
other patients treated for falciparum malaria at the same
time with the same batch of artesunate, suggests that per-
sistence of parasitaemia was unlikely to be due to poor
drug quality.
Delayed parasitic clearance has also been reported in
splenectomized individuals. In an early report of four
splenectomized patients with malaria, the clinical course
was found to be uncomplicated in all four patients, with
the parasite clearance delayed only in the one nonim-
mune patient and not in the other three partially immune
splenectomized patients [15]. In a subsequent report,
delayed parasite clearance was reported in a splenect-
omized patient with falciparum who was treated with
artemisinin derivatives [16]. In a more recent publication,
two splenectomized individuals had persistence of parasi-
taemia despite appropriate treatment and adequate
absorption with one patient not surviving the illness [17].
In this study both the patients were immune with a mod-
erate to high level of antibodies to P. falciparum. It is thus
unclear if splenectomy alone increases the risk of delayed
parasite clearance or if it needs to be associated with a low
immune or non-immune state. The patient described in
this case-report had an enlarged spleen (13.3 cm) on
ultrasound examination. There were no Howell-Jolly bod-
ies on the peripheral smear to suggest functional asplenia,
although their counting is not considered a reliable meas-
ure of splenic function [18].
Thus, persistence of parasitaemia in the patient reported
in this study is likely to be due to failure of intravenous
artesunate therapy. Whilst assessment of genetic polymor-
phism and inhibitory concentration of 50% (IC50) for
artemether would have been contributory to the assess-
Plain computed tomography (CT) scan of the head showing  bilateral subdural haematomas (marked by white arrows) Figure 3
Plain computed tomography (CT) scan of the head showing 
bilateral subdural haematomas (marked by white arrows).Malaria Journal 2008, 7:97 http://www.malariajournal.com/content/7/1/97
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ment of recrudescence, these could not be performed for
the patient presented in this case report.
Artemisinin resistance however is a contentious issue
[19]. In a retrospective study of 104 malaria patients, 32
of whom recrudesced, there were no differences in in vitro
artesunate sensitivities between 6 non-recrudescent iso-
lates and 16 paired admission and recrudescent isolates
[12]. The authors suggested that recrudescence with
artemisinin therapy was due to parasite density and not
due to inherent parasite resistance [12]. Other studies
have however suggested that genes that encode transport
proteins may be involved in drug resistance.
The commonly implicated mutations in drug resistance in
malaria are the pfmdr1 (Plasmodium falciparum multidrug
resistance gene 1) and pfcrt (Plasmodium falciparum chloro-
quine resistance transporter gene) genes [20]. An initial
study of 115 patients suggested that pfmdr1 gene was not
associated with treatment outcomes in patients treated
either with mefloquine or a combination of mefloquine
and artesunate [21]. However, more recently, an increase
in the pfmdr1 copy number was found to be associated
with up to a 40-fold decrease in the in vitro susceptibility
to mefloquine [20]. In the same study, a combination of
mefloquine-artemisinin was associated with increased
pfmdr1copy number through a 25-fold range of IC50 val-
ues [20]. The presence of parasites with three or more cop-
ies of pfmdr1 before treatment, in another study, was again
strongly associated with recrudescence [22], whilst
decreasing pfmdr1 copy number heightened susceptibility
to antimalarials [23]. It is now being suggested that poly-
morphisms in the gene encoding the sarco-endoplasmic
reticulum Ca2+-ATPase (SERCA) PfATP6  gene may be
associated with in vitro resistance to artemether in field
isolates of P falciparum [19].
It is again not clear as to why the patient reported in this
study failed to respond to doxycycline, added to the initial
treatment regime. Doxycycline has been recommended as
an alternative agent for the treatment [24] and prophy-
laxis of malaria [25] as well as adjunct therapy [26]. The
addition of doxycycline to a regimen of sulphadoxine/
pyrimethamine was associated with an improvement in
the cure rates from 78% to over 90% [26]. However, phar-
macokinetic studies suggest that the dosing of 200 mg per
day may not be optimal [27]. Further, it is well recognized
that oral absorption of drugs is significantly reduced in
the critically ill patient. It is likely that reduced absorption
of orally (nasogastrically) administered doxycycline in
sub-optimal doses in this critically ill patient may have
possibly contributed to the lack of response.
The occurrence of intracerebral haemorrhage or hae-
matoma is again a rare complication. The mechanism of
development of subdural haematoma in the patient
reported in this study was not evident. Although the fam-
ily denied history of trauma, this could not be ruled out
with certainty. It is likely that his subdural haematoma
was at least in part contributed by the thrombocytopenia.
However symptoms became evident in this patient much
after the platelet count started improving.
In a previous report, a three-year old girl with anaemia,
thrombocytopaenia and positive blood smear for falci-
parum malaria was diagnosed to have a spontaneous sub-
dural empyema [28]. This child was treated with surgical
evacuation, intravenous quinine and antibiotics [28]. In
another report, extensive subarachnoid haemorrhage was
described in a 54-year old woman that returned from
Kenya [29]. Focal haemorrhage has also been reported in
the left front falx of a patient diagnosed to have malaria
[30]. This is probably the first case of bilateral (spontane-
ous) subdural haematoma in association with falciparum
malaria.
Conclusion
Despite several strategies for malaria prevention and con-
trol, malaria continues to pose several public health chal-
lenges in the developing world. This case has been
reported to illustrate the occurrence of several rare and
alarming complications in one patient. An open and
inquisitive approach to the multiple symptoms of
patients presenting with malaria would enable the
prompt recognition of these complications and a success-
ful outcome.
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Table 2: Causes of abdominal pain in acute severe malaria
Organ Manifestation [reference number]
Abdomen (general) Acute surgical abdomen [3]
Spleen Splenic rupture [4]
Splenic infarction [5]
Splenic torsion [6]
Liver Hepatomegaly [1]
Hepatitis [1]
Gall bladder Acute acalculous cholecystitis [2]
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